FDA
-
-
-
-
-
-
-
BTIG Reiterates Buy Rating on Connect Biopharma Holdings Ltd (CNTB)
-
-
-
-
-
-
-
Results from Phase 3 Study of Rademikibart in Moderate-to-Severe Atopic Dermatitis to be Presented in the Late-Breaking Research Session at the 2026 American Academy of Dermatology (AAD) Annual Meetin
-
-
-
-
-
-
-
Connect Biopharma Presents Data Supporting Rademikibart at the European Respiratory Society Congress 2025
-
-
-
-
-
-
-
Connect Biopharma adds Jim Schoeneck to board of directors
-
-
-
-
-
-
-
Connect Biopharma (CNTB) Presents Data Supporting Rademikibart
-
-
-
-
-
-
-
Connect Biopharma Initiates Phase 2 Seabreeze STAT Asthma Study Evaluating Rademikibart for the Treatment of Acute Exacerbations in Asthma
-
-
-
-
-
-
-
Connect Biopharma Reports 2024 Full-Year Financial Results and Provides Business Update
-
323,707 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

